Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An antibody ...

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate ...

Schematic illustration of ErbB receptor structures and dimerization patterns ... powerful approach to overcome resistance. By combining HER3-targeting antibodies with cytotoxic payloads, ADCs ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

HER3 functions through its interaction with other ErbB receptors, particularly HER2, forming potent signaling pairs that drive cell survival, proliferation, and metastasis. These dimerized ...

Building upon the EpiClick platform, Tharimmune is also developing a new generation of multispecific antibodies targeting HER2 and HER3, two validated drivers of cancer growth and metastases.

Lastly, the HER3-DXd antibody-drug conjugate study presented a potential new therapy for patients with high-risk hormone receptor–positive, HER2-negative breast cancer in the neoadjuvant ...

Building upon the EpiClick platform, Tharimmune is also developing a new generation of multispecific antibodies targeting HER2 and HER3, two validated drivers of cancer growth and metastases.